Repositorio Institucional de la Universidad Alfonso X el Sabio

Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC)

Mostrar el registro sencillo del ítem

APA

Echarri González, Mª José & López Martín, Ana & Hitt Sabag, Ricardo (2016-02 ) .Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).

ISO 690

Echarri González, Mª José & López Martín, Ana & Hitt Sabag, Ricardo. 2016-02 .Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC).

https://hdl.handle.net/20.500.12080/39498
dc.contributor.author Echarri González, Mª José
dc.contributor.author López Martín, Ana
dc.contributor.author Hitt Sabag, Ricardo
dc.date.accessioned 2024-02-05T09:10:46Z
dc.date.available 2024-02-05T09:10:46Z
dc.date.created 2016-02
dc.date.issued 2016-02
dc.identifier.uri https://hdl.handle.net/20.500.12080/39498
dc.description.abstract Surgery and radiotherapy are the standard treatment options for patients with squamous cell carcinoma of the head and neck (SCCHN). Chemoradiotherapy is an alternative for patients with locally advanced disease. In recurrent/metastatic disease and after progression to platin-based regimens, no standard treatments other than best supportive care are currently available. Most SCCHN tumours overexpress the epidermal growth factor receptor (EGFR). This receptor is a tyrosine-kinase membrane receptor that has been implicated in angiogenesis, tumour progression and resistance to different cancer treatments. In this review, we analysed the different drugs and pathways under development to treat SCCHN, especially recurrent/metastatic disease. Until now, the EGFR signalling pathway has been considered the most important target with respect to new drugs; however, new drugs, such as immunotherapies, are currently under study. As new treatments for SCCHN are developed, the influence of therapies with respect to overall survival, progression free survival and quality of life in patients with this disease is changing. Keywords: SCCHN; signal transduction; EGFR; cetuximab; HNSCC es_ES
dc.format application/pdf es_ES
dc.language eng es_ES
dc.rights CC-BY es_ES
dc.rights.uri http://creativecommons.org/licenses/by/4.0/deed.es es_ES
dc.title Targeted Therapy in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (LA-R/M HNSCC) es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.rights.accessrights info:eu-repo/semantics/openAccess es_ES
dc.identifier.location N/A es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

CC-BY Excepto si se señala otra cosa, la licencia del ítem se describe como CC-BY

Buscar en DSpace


Listar

Mi cuenta

Social Media